Press Release

PathoQuest Announce the Opening of its New U.S. Facility
PathoQuest Announce the Opening of its New U.S. Facility

Press ReleaseThe Leading Experts in NGS Biosafety Testing and Characterization of Biopharmaceuticals Launch New Capabilities in the Critical U.S. MarketWayne, PA, and Paris, France – October 4, 2022 – PathoQuest, a leader in the development and provision of Next...

read more
PathoQuest Appoints Rainer Metzger, Ph.D. as Chairman of the Board of Directors
PathoQuest Appoints Rainer Metzger, Ph.D. as Chairman of the Board of Directors

Rainer Metzger works as a business professional in the Life Science and Pharmaceutical Industry. He has led numerous partnerships for co-development, commercialization, M&A and licensing. Rainer has been in leading positions in precision medicine, initiating and managing partnerships and services for clinical trials, co-development, and commercialization with QIAGEN, ROCHE, DANAHER and MEDICOVER establishing and running business with pharmaceutical companies. Rainer is acting as a board member for a series of Biotech companies in Europe and the US. He holds a Diploma in natural sciences and genetics and a PhD in Biology and Pharmacology from the University of Heidelberg.

read more
PathoQuest Receives GMP Certification for its NGS-based Quality Control Testing Services
PathoQuest Receives GMP Certification for its NGS-based Quality Control Testing Services

We are glad to announce today that PathoQuest has obtained a GMP certificate for its quality control testing activities at its French-based facilities in Paris (France), following a recent inspection by the French National Agency for the Safety of Medicine and Health Products (ANSM). PathoQuest is the first French CRO to offer GMP grade NGS-based testing services to assess the quality control of Human Medicinal Products and Human Investigational Medicinal Products.

read more
PathoQuest closes up to €15 million Series B financing round led by growth investor SHS Capital
PathoQuest closes up to €15 million Series B financing round led by growth investor SHS Capital

PathoQuesttoday announced the closing of a financing round up to €15M. This funding leverages the NGS technology in a proprietary approach to assess the viral safety and genetic characterization of biologics. It will support the development of PathoQuest’s US site (Wayne, PA), the expansion of the portfolio of NGS-based quality control (QC) tests and will accelerate its growth and market share worldwide.

read more

Click here to learn more about PathoQuest’s Biologics Genomic Service for biopharmaceutical companies.

Connect

 

EnglishFrenchGermanSpanish